Publication number: 20220387402
Abstract: In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
Type:
Application
Filed:
May 15, 2020
Publication date:
December 8, 2022
Applicant:
Pfizer Inc.
Inventors:
Gary E. Aspnes, Scott W. Bagley, John M. Curto, Matthew Dowling, David James Edmonds, Dilinie Fernando, Mark E. Flanagan, Kentaro Futatsugi, David Andrew Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Shawn M. LaCasse, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David Walter Piotrowski, Roger B. Ruggeri, Kristin Wiglesworth